-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Anika Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Anika Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $2.31M.
- Anika Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $2.99M.
- Anika Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was -$2.66M, a 31.6% increase from 2022.
- Anika Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was -$3.89M, a 128% decline from 2021.
- Anika Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was -$1.71M, a 63.2% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)